The funding will also allow the company to advance its tunable technology platform that has demonstrated regenerative potential beyond cornea, such as, for liver, lung and neuronal tissues
Pandorum Technologies, a leading biotechnology company, announced the successful closure of a pre-Series B funding round, securing $11 million (INR 88 crore) in investment. The funding was sourced from Ashish Kacholia, Everest Finance Investment, Acebright Pharma and Bandana Kankani’s syndicate along with existing investors Sunil Kant Munjal and the Indian Angel Network.
With the current round of funding, Pandorum aims to progress towards the First-in-Human study of its Flagship product Kuragenx- the ‘Liquid Cornea’, to treat corneal blindness. The funding will also allow the company to advance its tunable technology platform that has demonstrated regenerative potential beyond cornea, such as, for liver, lung and neuronal tissues.
“Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a First-in-Class approach that can truly blur the line between treatment and cure,” said Dr Tuhin Bhowmick, Co-Founder & CEO, Pandorum Technologies.
